Vanda Pharmaceuticals (VNDA) Profit After Tax (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Profit After Tax of -$48.6 million for Q1 2026, up 65.6% sequentially from -$141.2 million in Q4 2025, and down 64.67% YoY from -$137.5 million in Q1 2025.
Vanda Pharmaceuticals (VNDA) Profit After Tax (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Profit After Tax for 17 years, with the latest figure at -$48.6 million in Q1 2026.
- Quarterly Profit After Tax fell 64.67% year-over-year to -$48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$239.5 million (down 441.37% YoY) and the FY2025 annual result came in at -$220.5 million, down 1066.53% from the prior year.
- Profit After Tax improved to -$48.6 million in Q1 2026 per VNDA's latest filing, from -$141.2 million in the prior quarter.
- Over five years, Profit After Tax peaked at $6.9 million in Q4 2022 and troughed at -$141.2 million in Q4 2025.
- A 5-year average of -$16.4 million and a median of -$4.5 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax jumped 150.58% in 2023, then sank 3986.13% in 2024.
- Over 5 years, Profit After Tax stood at $6.9 million in 2022, then sank by 134.98% to -$2.4 million in 2023, then tumbled by 104.67% to -$4.9 million in 2024, then plunged by 2774.33% to -$141.2 million in 2025, then soared by 65.6% to -$48.6 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$48.6 million, -$141.2 million, and -$22.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | -62.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62.51 Mn |
| Mar 31, 2026 | -48.57 Mn |
| Dec 31, 2025 | -141.19 Mn |
| Sep 30, 2025 | -22.59 Mn |
| Jun 30, 2025 | -27.21 Mn |
| Mar 31, 2025 | -29.49 Mn |
| Dec 31, 2024 | -4.91 Mn |
| Sep 30, 2024 | -5.32 Mn |
| Jun 30, 2024 | -4.52 Mn |
| Mar 31, 2024 | -4.15 Mn |
| Dec 31, 2023 | -2.40 Mn |
| Sep 30, 2023 | 137,000.00 |
| Jun 30, 2023 | 1.52 Mn |
| Mar 31, 2023 | 3.25 Mn |
| Dec 31, 2022 | 6.86 Mn |
| Sep 30, 2022 | 3.27 Mn |
| Jun 30, 2022 | 2.57 Mn |
| Mar 31, 2022 | -6.43 Mn |
| Dec 31, 2021 | 7.08 Mn |
| Sep 30, 2021 | 7.77 Mn |